Transparency Market Research in its new report titled, “Recombinant Vector Vaccines Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 – 2025,” provides key insights on the recombinant vector vaccines market. The new report states that the rapid development in molecular biology and genetic engineering will drive the recombinant vector vaccines market during the forecast period i.e, 2017 – 2025. The market is expected to show a rapid growth during the forecast period. However, substantial number of pharmaceutical challenges associated with the development of recombinant vector vaccines and stringent regulatory norms laid by the regulatory bodies is likely to restrain the market, mentions the TMR report.
Recombinant vector vaccine strategy enables triggering of T- lymphocyte, and antigens, are thus presented to T- cell lymphocytes, which generates a strong cell mediated immune response in the body against that particular antigen or microbe. Moreover, it reduces need of repeat dosage to treat a particular disease. Attenuated bacterium can also be used as an efficient vector to generate recombinant vector vaccines. In this case, genetic material is inserted into the bacterial vector, causing the bacteria to express the antigens of other microorganism onto its surface, generating an immune response.
The TMR report has segregated the global recombinant vector vaccines market based on type of vector, disease type, and region. In accordance with type of vector, the market is bifurcated into recombinant viral vector vaccines and recombinant bacterial vector vaccines. The recombinant viral vector vaccines segment holds the majority share of the market. In terms of disease type, the market is split into vector vaccines used to treat various viral and bacterial infections. Recombinant vector vaccines are being developed to treat cancer.
Based on regional perspective, the global recombinant vector vaccines market is divided into Europe, Asia Pacific, Latin America, North America, and Middle East & Africa. North America dominated the market in 2016, due to rise in technology advancements in molecular biology and genetic engineering. Increasing awareness, government initiatives, and availability of vector vaccines are expected to boost the growth of the market in Asia Pacific, as per the report. The recombinant vector vaccines market in Europe is also anticipated to grow during the forecast period owing to technological developments and increasing prevalence of infectious diseases.
Major players in the global recombinant vector vaccines market are profiled in this report to give a better competitive analysis and these include Sanofi, Pfizer, Inc., Novartis AG, Neuron Biotech, Merck and Company, GlaxoSmithKline plc, CSL Limited, Biological E, and Bharat Biotech.
About Us
Transparency Market Research is a next-generation market intelligence provider, offering fact-based solutions to business leaders, consultants, and strategy professionals. We are leaders in analytics, research, and advisory services for Fortune 500 companies, scores of high potential startups, and financial institutions. Our success stories have proven why we are a preeminent provider of cutting-edge syndicated and customized research services. Leverage the best of our seasoned research analysts who hold a keen interest and enviable expertise of almost 4 million hours in global, regional, and local market intelligence. TMR believes that unison of solutions for clients-specific problems with right methodology of research is the key to help enterprises reach right decision.
US Office Contact
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Website: https://www.transparencymarketresearch.com
Email: [email protected]